Clinical

Dataset Information

0

A phase II study of up-front red blood cell transfusion before chemotherapy followed by maintenance Erythropoetin-alpha subcutaneous support during chemotherapy of anaemic breast-, colorectal- and ovarian cancer patients


ABSTRACT: Study hypothesis: An upfront Red Blood Cell Transfusion (RBCT) aiming at low-normal Haemoglobin (Hb) levels will ameliorate anemia-caused tumour hypoxia-related resistance to chemotherapy before the start of chemotherapy and may decrease secondary anemia-induced endogenous release of cytokines like Vascular Endothelial Growth Factor (VEGF), osteopontin. The maintenance of optimal Hb levels at this lower-normal range during chemotherapy by weekly maintenance administration of Erythropoetin-alpha (Epo-alpha) subcutaneous (s.c.) at doses with proven safety and efficacy creates optimal conditions for tumour oxygenation, without the presumably high-Hb level associated adverse effects. Primary outcome(s): 1. Hb levels before the start of and during chemotherapy 2. Safety of the pCATS anaemia treatment regimen

DISEASE(S): Ovarian Cancer,Colorectal Cancer,Breast Cancer,Solid Tumors

PROVIDER: 2424172 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2019-07-15 | GSE110867 | GEO
2019-07-15 | GSE110866 | GEO
2019-07-15 | GSE110868 | GEO
2009-09-15 | GSE16334 | GEO
2009-09-18 | E-GEOD-16334 | biostudies-arrayexpress
2016-04-05 | GSE73753 | GEO
2019-01-01 | GSE107705 | GEO
2017-11-21 | GSE104766 | GEO
2009-09-15 | E-MEXP-2263 | biostudies-arrayexpress
2015-02-04 | E-GEOD-65577 | biostudies-arrayexpress